Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Phase 2(2)

Phase 1(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01806961Terminated

Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.

Role: lead

NCT01808950Phase 1Terminated

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Role: lead

NCT01146444Not ApplicableCompleted

Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)

Role: lead

NCT01532453Phase 3Terminated

Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients

Role: lead

NCT01583816Phase 2Completed

Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

Role: lead

NCT01792713Phase 2Completed

Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

Role: lead

All 6 trials loaded